<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell J</journal-id><journal-id journal-id-type="iso-abbrev">Cell J</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>Cell Journal (Yakhteh)</journal-title></journal-title-group><issn pub-type="ppub">2228-5806</issn><issn pub-type="epub">2228-5814</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36043411</article-id><article-id pub-id-type="pmc">PMC9428472</article-id><article-id pub-id-type="other">Cell-J-24-424</article-id><article-id pub-id-type="doi">10.22074/cellj.2022.8487</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to The Editor</subject><subj-group><subject>Virology</subject><subject>Biology</subject></subj-group></subj-group></article-categories><title-group><article-title>Hypertension in COVID-19, A Risk Factor for Infection or
A Late Consequence? </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Barekat</surname><given-names>Maryam</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="con1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Shahrbaf</surname><given-names>Mohammad Amin</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="con1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Rahi</surname><given-names>Kosar</given-names></name><degrees>M.Sc</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Vosough</surname><given-names>Massoud</given-names></name><degrees>M.D., Ph.D</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="A1"><label>1</label>Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR,
Tehran, Iran</aff><aff id="A2"><label>2</label>Research and Development Department, Royan Stem Cell Technology Co, Tehran, Iran</aff><aff id="A3"><label>3</label>Experimental Cancer Medicine, Institution for Laboratory Medicine, Karolinska Institute, Stockholm, Sweden</aff></contrib-group><author-notes><corresp id="cor1">
<label> *Corresponding Address:</label>
<addr-line>P.O.Box: 16635-148</addr-line>
<addr-line>Department of Regenerative Medicine</addr-line>
<addr-line>Cell Science Research Center</addr-line>
<institution>Royan Institute for
Stem Cell Biology and Technology</institution>
<addr-line>ACECR</addr-line>
<addr-line>Tehran</addr-line>
<country>Iran</country>
Email:<email>masvos@royaninstitute.org</email>
</corresp><fn id="con1"><label>#</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>7</month><year>2022</year></pub-date><volume>24</volume><issue>7</issue><fpage>424</fpage><lpage>426</lpage><history><date date-type="received"><day>27</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2022</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium,
with the exception of commercial purposes, is permitted provided the original work is properly cited.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited. </license-p></license></permissions><abstract><p>There are a lot of data about the correlation of SARS-CoV-2 infection and hypertension (HTN), but most of them
are in the increased risk of morbidity and mortality in patients with HTN. SARS-CoV-2 can interfere with host cells
through the renin-angiotensin system (RAS) via the angiotensin-converting enzyme 2 (ACE2) receptor. RAS activation
is associated with pro-inflammatory effects through the ACE/Ang II/ Angiotensin II type 1 receptor (AT1R) pathway
or anti-inflammatory effects through ACE2/Ang1-7/Mas axis. In the current paper, we discuss the pathophysiology of
newly diagnosed HTN and its effect on morbidity in patients with coronavirus disease 2019 (COVID-19). </p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>Hypertension</kwd><kwd>Renin-Angiotensin-Aldosterone System</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Barekat M, Shahrbaf MA, Rahi K, Vosough M. Hypertension in COVID-19, a risk factor for infection or a late consequence? Cell J. 2022; 24(7): 424-
426. doi: 10.22074/cellj.2022.8487.
This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Coronavirus disease 2019 (COVID-19), caused
by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) firstly reported in Wuhan in 2019 (<xref rid="B1" ref-type="bibr">1</xref>),
China, that caused more than 517 million confirmed
cases and almost 6.2 million deaths until 6 May 2022
(<xref rid="B2" ref-type="bibr">2</xref>). It is shown that cardiovascular diseases and risk
factors such as hypertension (HTN) are associated
with more severe symptoms in affected individuals
including dyspnea, and hypoxia. These patients need
intensive care unit (ICU) that represent the increased
likelihood of morbidities, and even mortality (<xref rid="B3" ref-type="bibr">3</xref>).
On the other hand, HTN may be a consequence of
COVID-19, due to the over-activity of the reninangiotensin system (RAS) (<xref rid="B4" ref-type="bibr">4</xref>).
</p><p>During the COVID-19 pandemic disease, especially
during lockdown and quarantine, diagnostic and
therapeutic interventions for HTN were reduced
significantly, which deteriorates the long-term
consequences of HTN and cardiovascular events (<xref rid="B5" ref-type="bibr">5</xref>,
<xref rid="B6" ref-type="bibr">6</xref>). In addition, studies reported that the COVID-19
pandemics has changed the treatment strategies of HTN
in order to have a better management of this condition
in patients (<xref rid="B7" ref-type="bibr">7</xref>). In this study, we review the association
between COVID-19 and HTN as a risk factor for the
infection, and a consequence of the infection.</p><sec><title>COVID-19 and RAS</title><p>SARS-CoV-2 penetrates host cells using surface
spike protein through the angiotensin-converting
enzyme 2 (ACE2) receptor that interferes with
host cells via RAS (<xref rid="B8" ref-type="bibr">8</xref>). Recent studies showed that
RAS over-activation might have pro-inflammatory,
profibrotic, and vasoconstrictive effects by reactive
oxygen species (ROS) production and cytokines release
through ACE/Ang II/ Angiotensin II type 1 receptor
(AT1
R) pathway (<xref rid="B9" ref-type="bibr">9</xref>). However, RAS can act through
an alternative pathway, the ACE2/Ang1-7/Mas axis,
which is a counter-regulator of classic pathway causing
anti-inflammatory effects (<xref rid="B10" ref-type="bibr">10</xref>). It was revealed that,
the ACE2/Ang1-7/Mas axis, may be downregulated
in COVID-19 infection due to eliminating ACE2
expressing cells by virus. This issue may cause the over
expression of ACE/Ang II/AT1
R pathway (<xref rid="B11" ref-type="bibr">11</xref>). Since
angiotensin II receptor blockers, ACE inhibitors, and
mineralocorticoid receptor antagonists overexpressed
the ACE2 receptor, it has been thought that these drugs
can lessen the severity of the disease and cause ACE2/
Ang1-7/Mas axis upregulation. These properties
associated with beneficial effects on lung function.
Therefore, these drugs should not be withheld during
COVID-19 (<xref rid="B12" ref-type="bibr">12</xref>).</p></sec><sec><title>Inflammation</title><p>SARS-CoV-2 infection can induce cytokine storm
via different mechanisms. The activation of Ang II,
which promotes production of pro-inflammatory
cytokines such as IL-6 and TNF-alpha causing an
influx of inflammatory cells to the infected sites results in vascular injury, fibrosis and even thrombosis
(<xref rid="B13" ref-type="bibr">13</xref>). In addition, SARS-CoV-2 infection can induce
production of ROS, which stimulates the synthesis
of NF-&#x003ba;B (<xref rid="B14" ref-type="bibr">14</xref>). This usually results in increment of
cytokines and the cytokine storm (<xref rid="B15" ref-type="bibr">15</xref>). On the other
hand, the role of inflammation in HTN has been
investigated. It seems that systemic inflammation may
cause arterial stiffness associated with elevating blood
pressure until the rage of HTN (<xref rid="B16" ref-type="bibr">16</xref>). In fact, oxidative
stress alongside chronic inflammation causes changing
the arterial walls, increase in intima-media thickness,
and endothelial dysfunction (<xref rid="B17" ref-type="bibr">17</xref>). </p><p>It was shown that endothelial dysfunction may
be associated with essential HTN (<xref rid="B18" ref-type="bibr">18</xref>) and severe
endothelial injury in the severe COVID-19 (<xref rid="B19" ref-type="bibr">19</xref>). It
seems that endothelial dysfunction resulted from HTN,
may exacerbate COVID-19 symptoms in patients
with HTN; also, and in some patients without HTN,
endothelial dysfunction resulted from COVID-19
infection may develop HTN in near future.
</p></sec><sec><title>Hypertension: a risk factor for COVID19 or its
consequence?</title><p>The endothelial dysfunction caused by HTN may
influence the outcome of COVID-19. In the evaluation
of newly onset HTN in COVID-19, there are many
of studies that supported this concept. In a study in
late 2021 on 211 COVID-19 patients, new onset
HTN was seen in 18 patients during a 30-day followup (<xref rid="B20" ref-type="bibr">20</xref>). In another study by Chen et al. (<xref rid="B4" ref-type="bibr">4</xref>) on 366
patients, new onset HTN was observed in 190 patients
without history of HTN, with high levels of Ang II and
cardiac troponin. In addition, Bekbossynova et al. (<xref rid="B21" ref-type="bibr">21</xref>)
observed a case of COVID-19 that was manifested as
sudden HTN. However, conflicting results observed in
a cohort study in China on more than 1,700 COVID-19
patients with a six months follow-up, without reports
of newly diagnosed HTN (<xref rid="B7" ref-type="bibr">7</xref>). </p><p>According to our explorations, there is a close
relationship between HTN and COVID-19 infection.
Each of them can induce and exacerbate the other one;
although, more studies are needed to investigate new
onset HTN after COVID-19.</p></sec><sec><title>How should we battle?</title><p>It was suggested that the mortality rate is similar in
adjusted model analysis, in the context of beta blocker,
ACEIs or ARBs consumption in COVID-19 patients
(<xref rid="B22" ref-type="bibr">22</xref>). Furthermore, large scale studies reduced the
uncertainties in the context of medication controversies
in COVID-19 patients with HTN; however, further
cohort studies are needed to confirm this hypothesis.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>According to our explorations, there is a close association
between HTN and COVID-19 infection. Each of them can
induce and exacerbate the other one; although, to have a
better insight, more studies are needed to investigate new
onset HTN after COVID-19.</p></sec></body><back><ack><title>Acknowledgements</title><p>There is no financial support and conflict of interest in
this study.</p></ack><bio id="d64e240"><title>Authors&#x02019; Contributions</title><p>M.B., M.V.; Contributed to conception and design.
M.A.S., K.R.; Drafted the manuscript, which was revised
by M.B. and M.V. All authors read and approved the final
manuscript.</p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="webpage"><comment>Available from: <uri xlink:href="https://covid19.who.int/">https://covid19. who.int/</uri> (13 May 2022).
</comment></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahrbaf</surname><given-names>MA</given-names></name>
<name><surname>Hassan</surname><given-names>M</given-names></name>
<name><surname>Vosough</surname><given-names>M</given-names></name>
</person-group><article-title>COVID-19 and Hygiene Hypothesis: increment of the Inflammatory Bowel Diseases in next generation?</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2022</year><volume>16</volume><issue>1</issue><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">34919489</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savoia</surname><given-names>C</given-names></name>
<name><surname>Volpe</surname><given-names>M</given-names></name>
<name><surname>Kreutz</surname><given-names>R</given-names></name>
</person-group><article-title>Hypertension, a moving target in COVID-19: current views and perspectives</article-title><source>Circ Res</source><year>2021</year><volume>128</volume><issue>7</issue><fpage>1062</fpage><lpage>1079</lpage><pub-id pub-id-type="pmid">33793331</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Gong</surname><given-names>Z</given-names></name>
<name><surname>Xia</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Hypertension as a sequela in patients of SARS-CoV-2 infection</article-title><source>PLoS One</source><year>2021</year><volume>16</volume><issue>4</issue><fpage>e0250815</fpage><lpage>e0250815</lpage><pub-id pub-id-type="pmid">33909683</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>T</given-names></name>
<name><surname>Amar</surname><given-names>J</given-names></name>
<name><surname>de Backer</surname><given-names>T</given-names></name>
<name><surname>Burkard</surname><given-names>T</given-names></name>
<name><surname>van der Giet</surname><given-names>M</given-names></name>
<name><surname>Gosse</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension</article-title><source>Blood Press</source><year>2022</year><volume>31</volume><issue>1</issue><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">35465794</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burnier</surname><given-names>M</given-names></name>
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<name><surname>Narkiewicz</surname><given-names>K</given-names></name>
<name><surname>Egan</surname><given-names>B</given-names></name>
<name><surname>Kreutz</surname><given-names>R</given-names></name>
</person-group><article-title>Hypertension management during the COVID-19 pandemic: what can we learn for the future?</article-title><source>Blood Press</source><year>2022</year><volume>31</volume><issue>1</issue><fpage>47</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">35426323</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Huang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
<name><surname>Gu</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study</article-title><source>Lancet</source><year>2021</year><volume>397</volume><issue>10270</issue><fpage>220</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">33428867</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J</given-names></name>
<name><surname>Petitjean</surname><given-names>SJL</given-names></name>
<name><surname>Koehler</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Dumitru</surname><given-names>AC</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<etal/>
</person-group><article-title>Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>4541</fpage><lpage>4541</lpage><pub-id pub-id-type="pmid">32917884</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benigni</surname><given-names>A</given-names></name>
<name><surname>Cassis</surname><given-names>P</given-names></name>
<name><surname>Remuzzi</surname><given-names>G</given-names></name>
</person-group><article-title>Angiotensin II revisited: new roles in inflammation, immunology and aging</article-title><source>EMBO Mol Med</source><year>2010</year><volume>2</volume><issue>7</issue><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">20597104</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Capettini</surname><given-names>LS</given-names></name>
<name><surname>Montecucco</surname><given-names>F</given-names></name>
<name><surname>Mach</surname><given-names>F</given-names></name>
<name><surname>Stergiopulos</surname><given-names>N</given-names></name>
<name><surname>Santos</surname><given-names>RA</given-names></name>
<name><surname>da Silva</surname><given-names>RF</given-names></name>
</person-group><article-title>Role of renin-angiotensin system in inflammation, immunity and aging</article-title><source>Curr Pharm Des</source><year>2012</year><volume>18</volume><issue>7</issue><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="pmid">22283774</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Issa</surname><given-names>H</given-names></name>
<name><surname>Eid</surname><given-names>AH</given-names></name>
<name><surname>Berry</surname><given-names>B</given-names></name>
<name><surname>Takhviji</surname><given-names>V</given-names></name>
<name><surname>Khosravi</surname><given-names>A</given-names></name>
<name><surname>Mantash</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Combination of angiotensin (1-7) agonists and convalescent plasma as a new strategy to overcome angiotensin converting enzyme 2 (ACE2) inhibition for the treatment of COVID-19</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>620990</fpage><lpage>620990</lpage><pub-id pub-id-type="pmid">33816521</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brojakowska</surname><given-names>A</given-names></name>
<name><surname>Narula</surname><given-names>J</given-names></name>
<name><surname>Shimony</surname><given-names>R</given-names></name>
<name><surname>Bander</surname><given-names>J</given-names></name>
</person-group><article-title>Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC review topic of the week</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>75</volume><issue>24</issue><fpage>3085</fpage><lpage>3095</lpage><pub-id pub-id-type="pmid">32305401</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tay</surname><given-names>MZ</given-names></name>
<name><surname>Poh</surname><given-names>CM</given-names></name>
<name><surname>R&#x000e9;nia</surname><given-names>L</given-names></name>
<name><surname>MacAry</surname><given-names>PA</given-names></name>
<name><surname>Ng</surname><given-names>LFP</given-names></name>
</person-group><article-title>The trinity of COVID-19: immunity, inflammation and intervention</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>363</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">32346093</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Shahriari-Felordi</surname><given-names>M</given-names></name>
<name><surname>Alikhani</surname><given-names>HK</given-names></name>
<name><surname>Hashemian</surname><given-names>SM</given-names></name>
<name><surname>Hassan</surname><given-names>M</given-names></name>
<name><surname>Vosough</surname><given-names>M</given-names></name>
</person-group><source>Mini review ATF4 and GRP78 as novel molecular targets in ER-Stress modulation for critical COVID-19 patients.Mol Biol Rep</source><publisher-name>Mol Biol Rep</publisher-name><year>2022</year><fpage>1</fpage><lpage>5</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhaskar</surname><given-names>S</given-names></name>
<name><surname>Sinha</surname><given-names>A</given-names></name>
<name><surname>Banach</surname><given-names>M</given-names></name>
<name><surname>Mittoo</surname><given-names>S</given-names></name>
<name><surname>Weissert</surname><given-names>R</given-names></name>
<name><surname>Kass</surname><given-names>JS</given-names></name>
<etal/>
</person-group><article-title>Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><fpage>1648</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">32754159</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomiyama</surname><given-names>H</given-names></name>
<name><surname>Shiina</surname><given-names>K</given-names></name>
<name><surname>Matsumoto-Nakano</surname><given-names>C</given-names></name>
<name><surname>Ninomiya</surname><given-names>T</given-names></name>
<name><surname>Komatsu</surname><given-names>S</given-names></name>
<name><surname>Kimura</surname><given-names>K</given-names></name>
<etal/>
</person-group><article-title>The contribution of inflammation to the development of hypertension mediated by increased arterial stiffness</article-title><source>J Am Heart Assoc</source><year>2017</year><volume>6</volume><issue>7</issue><fpage>e005729</fpage><lpage>e005729</lpage><pub-id pub-id-type="pmid">28666991</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castellon</surname><given-names>X</given-names></name>
<name><surname>Bogdanova</surname><given-names>V</given-names></name>
</person-group><article-title>Chronic inflammatory diseases and endothelial dysfunction</article-title><source>Aging Dis</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">26815098</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faulkner</surname><given-names>JL</given-names></name>
<name><surname>Belin de Chantem&#x000e8;le</surname><given-names>EJ</given-names></name>
</person-group><article-title>Mineralocorticoid receptor and endothelial dysfunction in hypertension</article-title><source>Curr Hypertens Rep</source><year>2019</year><volume>21</volume><issue>10</issue><fpage>78</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">31485760</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruhl</surname><given-names>L</given-names></name>
<name><surname>Pink</surname><given-names>I</given-names></name>
<name><surname>K&#x000fc;hne</surname><given-names>JF</given-names></name>
<name><surname>Beushausen</surname><given-names>K</given-names></name>
<name><surname>Keil</surname><given-names>J</given-names></name>
<name><surname>Christoph</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>418</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">34893580</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Akpek</surname><given-names>M</given-names></name>
</person-group><source>Does COVID-19 cause hypertension?.Angiology</source><publisher-name>Angiology</publisher-name><year>2021</year><fpage>33197211053903</fpage><lpage>33197211053903</lpage></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bekbossynova</surname><given-names>M</given-names></name>
<name><surname>Ainur</surname><given-names>T</given-names></name>
</person-group><article-title>Hypertension as a manifestation of COVID-19 pneumonia</article-title><source>Clin Case Rep</source><year>2021</year><volume>9</volume><issue>9</issue><fpage>e04720</fpage><lpage>e04720</lpage><pub-id pub-id-type="pmid">34484759</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tadic</surname><given-names>M</given-names></name>
<name><surname>Saeed</surname><given-names>S</given-names></name>
<name><surname>Grassi</surname><given-names>G</given-names></name>
<name><surname>Taddei</surname><given-names>S</given-names></name>
<name><surname>Mancia</surname><given-names>G</given-names></name>
<name><surname>Cuspidi</surname><given-names>C</given-names></name>
</person-group><article-title>Hypertension and COVID-19: ongoing controversies</article-title><source>Front Cardiovasc Med</source><year>2021</year><volume>8</volume><fpage>639222</fpage><lpage>639222</lpage><pub-id pub-id-type="pmid">33681308</pub-id></element-citation></ref></ref-list></back></article>
